Blog

Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari

Photos of Rahul and Rohit Gosain, and Arvind Dasari

Apr 29, 2024, 07:58

Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

“GISeries: In this episode, we get a chance to discuss FDA approval of Fruquintinib from FRESCO2 and how it fits in our treatment paradigm with N. Arvind Dasari.

Full Interview:
– On Targeted Oncology,
– On OncBrothers,
– Also on the ‘Oncology Brothers’ podcast.”

View the attached video.
Source: Rahul Gosain/LinkedIn

cancer colorectal cancer CRC FDA FDA approval FRESCO2 trial Fruquintinib N. Arvind Dasari OncoDaily Oncology Oncology Brothers Rahul Gosain refractory CRC Targeted Oncology Wilmot Cancer Institute

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success